×
About 1,879 results

ALLMedicine™ Branch Retinal Vein Occlusion Center

Research & Reviews  911 results

Effect of intravitreal dexamethasone implant versus ranibizumab on vessel density in br...
https://doi.org/10.1177/11206721211008354
European Journal of Ophthalmology; Kaya M, Ozturk T et. al.

Apr 8th, 2021 - This study aimed to compare the effect of intravitreal dexamethasone implant with that of ranibizumab on vessel density (VD) in eyes with branch retinal vein occlusion (BRVO). Sixty-three eyes of 63 patients with superotemporal BRVO treated either...

Iatrogenic Vitreous Hemorrhage, Subretinal Hemorrhage, and Branch Retinal Vein Occlusio...
https://doi.org/10.1016/j.ophtha.2020.10.026
Ophthalmology Shields RA, Cheng OT et. al.

Mar 22nd, 2021 - Iatrogenic Vitreous Hemorrhage, Subretinal Hemorrhage, and Branch Retinal Vein Occlusion after YAG Laser Vitreolysis for Symptomatic Vitreous Floaters.|2021|Shields RA,Cheng OT,Wolfe JD,|

Risk factors for repeated dexamethasone intravitreal implant therapy for macular edema ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981849
BMC Ophthalmology; Huang YT, Lin CJ et. al.

Mar 21st, 2021 - This study evaluated the effects of dexamethasone intravitreal implant on treatment-naïve branch retinal vein occlusion (BRVO)-induced macular edema (ME), and the risk factors for earlier repeated treatment. Patients treated from 2013 to 2016 were...

Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch re...
https://doi.org/10.1136/bjophthalmol-2020-318491
The British Journal of Ophthalmology; Hunt AR, Nguyen V et. al.

Mar 13th, 2021 - To compare the efficacy of ranibizumab (0.5 mg) with aflibercept (2 mg) in the treatment of cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months. A multicentre, international, database observational study recruited 322...

see more →

Guidelines  1 results

Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion: A Report by the A...
https://www.aaojournal.org/article/S0161-6420(17)30980-6/fulltext
Justis P. Ehlers

Aug 31st, 2017 - Current level I evidence suggests that intravitreal pharmacotherapy with anti-VEGF agents is effective and safe for ME secondary to BRVO. Prolonged delay in treatment is associated with less improvement in visual acuity (VA).

see more →

Drugs  1 results see all →

Clinicaltrials.gov  943 results

Effect of intravitreal dexamethasone implant versus ranibizumab on vessel density in br...
https://doi.org/10.1177/11206721211008354
European Journal of Ophthalmology; Kaya M, Ozturk T et. al.

Apr 8th, 2021 - This study aimed to compare the effect of intravitreal dexamethasone implant with that of ranibizumab on vessel density (VD) in eyes with branch retinal vein occlusion (BRVO). Sixty-three eyes of 63 patients with superotemporal BRVO treated either...

Iatrogenic Vitreous Hemorrhage, Subretinal Hemorrhage, and Branch Retinal Vein Occlusio...
https://doi.org/10.1016/j.ophtha.2020.10.026
Ophthalmology Shields RA, Cheng OT et. al.

Mar 22nd, 2021 - Iatrogenic Vitreous Hemorrhage, Subretinal Hemorrhage, and Branch Retinal Vein Occlusion after YAG Laser Vitreolysis for Symptomatic Vitreous Floaters.|2021|Shields RA,Cheng OT,Wolfe JD,|

Risk factors for repeated dexamethasone intravitreal implant therapy for macular edema ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981849
BMC Ophthalmology; Huang YT, Lin CJ et. al.

Mar 21st, 2021 - This study evaluated the effects of dexamethasone intravitreal implant on treatment-naïve branch retinal vein occlusion (BRVO)-induced macular edema (ME), and the risk factors for earlier repeated treatment. Patients treated from 2013 to 2016 were...

Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch re...
https://doi.org/10.1136/bjophthalmol-2020-318491
The British Journal of Ophthalmology; Hunt AR, Nguyen V et. al.

Mar 13th, 2021 - To compare the efficacy of ranibizumab (0.5 mg) with aflibercept (2 mg) in the treatment of cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months. A multicentre, international, database observational study recruited 322...

see more →

News  23 results

Aflibercept Superior to Photocoagulation for Macular Edema?
https://www.medscape.com/viewarticle/840759

Mar 4th, 2015 - Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: The 24-Week Results of the VIBRANT Study Campochiaro PA, Clark WL, Boyer DS, et al Ophthalmology. 2015;122:538-544 Study Summary The VIBRANT study was a 24-week, d...

Visual Gains With Aflibercept Upheld at 52 Weeks in VIBRANT
https://www.medscape.com/viewarticle/836129

Dec 7th, 2014 - CHICAGO — For patients with macular edema related to branch retinal vein occlusion, monthly intravitreal aflibercept (Eylea, Regeneron) injections can lead to visual gains at 24 weeks that are maintained at 52 weeks, report investigators from the ...

Aflibercept Injections Superior to Laser for Macular Edema
https://www.medscape.com/viewarticle/824870

May 7th, 2014 - ORLANDO, Florida — Macular edema secondary to branch retinal vein occlusion is treated more effectively with monthly intravitrial injections of the vascular endothelial growth-factor (VEGF) inhibitor aflibercept than with laser therapy, a new phas...

VEGF Inhibition Improves Visual Acuity in Macular Edema
https://www.medscape.com/viewarticle/823547

Apr 11th, 2014 - TOKYO — Ranibizumab (Lucentis, Genentech, Inc) is associated with significant improvement in visual acuity in patients with macular edema secondary to branch retinal vein occlusion, a new study shows. Improvement was seen whether or not the patien...

BRVO: Natural History Knowledge Can Guide Prognosis
https://www.medscape.com/viewarticle/814084

Nov 7th, 2013 - Distinguishing between the 2 clinical variations of branch retinal vein occlusion (BRVO),major and macular BRVO, is important for prognosis, according to a new study of the natural history of the disease. Theis study was published online October 2...

see more →